Italy Blood Cancer Diagnostics Market Size & Outlook
Related Markets
Italy blood cancer diagnostics market highlights
- The Italy blood cancer diagnostics market generated a revenue of USD 336.8 million in 2024 and is expected to reach USD 514.0 million by 2030.
- The Italy market is expected to grow at a CAGR of 7.3% from 2025 to 2030.
- In terms of segment, assay kits and reagents was the largest revenue generating product in 2024.
- Assay Kits and Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
Blood cancer diagnostics market data book summary
| Market revenue in 2024 | USD 336.8 million |
| Market revenue in 2030 | USD 514.0 million |
| Growth rate | 7.3% (CAGR from 2025 to 2030) |
| Largest segment | Assay kits and reagents |
| Fastest growing segment | Assay Kits and Reagents |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Assay Kits and Reagents |
Other key industry trends
- In terms of revenue, Italy accounted for 3.1% of the global blood cancer diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany blood cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 1,080.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood Cancer Diagnostics Market Scope
Blood Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| SkylineDx | View profile | 11-50 | Rotterdam, Zuid-Holland, The Netherlands, Europe | http://www.skylinedx.com/ |
| Invivoscribe, Inc. | View profile | 251-500 | San Diego, California, United States, North America | https://www.invivoscribe.com |
| Abbott | View profile | - | - | - |
| QIAGEN | View profile | - | - | - |
| Danaher Corporation | View profile | - | - | - |
| Adaptive Biotechnologies | View profile | 501-1000 | Seattle, Washington, United States, North America | http://adaptivebiotech.com |
| Sophia Genetics SA | View profile | 449 | La Pièce 12, Rolle, Switzerland, CH-1180 | https://www.sophiagenetics.com |
| Bio-Techne Corp | View profile | 3050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | https://www.bio-techne.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
Italy blood cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Assay kits and reagents was the largest segment with a revenue share of 72.12% in 2024. Horizon Databook has segmented the Italy blood cancer diagnostics market based on instruments, assay kits and reagents covering the revenue growth of each sub-segment from 2018 to 2030.
The driving factors in Italy for the blood cancer diagnostics market are primarily related to advancements in molecular testing and the need for more accurate & efficient diagnostic tools. Furthermore, the increasing focus on precision medicine and personalized treatment approaches has driven the demand for advanced diagnostic technologies, such as metabolomics, to better understand the metabolic rewiring associated with cancer and develop more effective therapeutic strategies.
These factors collectively contribute to the growth and development of blood cancer diagnostics kits & assays in Italy. In March 2020, Japan's AGC (formerly Asahi Glass Chemical) launched a voluntary tender offer to acquire the Italian clinical-stage biotech company Molecular Medicine (Molmed).
Molmed is focused on research, development, manufacturing, and clinical validation of gene & cell therapies, and it offers GMP services for third parties, including leading European and U.S. companies. Molmed's most advanced product is a Chimeric Antigen Receptor-T (CAR-T) cell therapy for acute myeloid leukemia and multiple myeloma. In addition, it is developing a pipeline based on natural killer cells. Such advances are driving market growth.
Reasons to subscribe to Italy blood cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Italy blood cancer diagnostics market databook
-
Our clientele includes a mix of blood cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Italy blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Italy blood cancer diagnostics market size, by test, 2018-2030 (US$M)
Italy Blood Cancer Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
